Aligos Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Aligos Therapeutics, Inc. (ALGS) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $12.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $11.74M, a 68.07% decline year-over-year.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $36.77M.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$111.41M.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.40M.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$18.69M.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$98.67M, a 281.67% decline from fiscal 2023.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $54.31M.
- Aligos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$105.52M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.01M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $11.74M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$18.69M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $4.95M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$18.34M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $36.77M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$98.67M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$100.33M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$90.63M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$111.41M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $54.31M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | -$10.96M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $9.41M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$2.40M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$105.52M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | -$100.46M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$115.79M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$80.86M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$33.96M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $19.44M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | -$33.10M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$20.02M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $150.84M 10-K · filed 2022-03-10 | |||
| 2020-09-30 | -$37.73M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | -$46.87M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$44.14M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $45.56M 10-K · filed 2021-03-23 | |||
| 2019-09-30 | -$2.88M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |